These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25975302)

  • 1. [Sequential Treatment of Advanced Squamous Lung Cancer: 
First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
    Xu J; Liu X; Gao H; Guo W; Tang C; Li X; Li J; Qin H; Wang W; Qu L; Wang H; Yang H; Yang L
    Zhongguo Fei Ai Za Zhi; 2015 May; 18(5):308-14. PubMed ID: 25975302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
    Giannatempo P; Pond GR; Sonpavde G; Raggi D; Naik G; Galsky MD; Bellmunt J; Necchi A
    Eur Urol; 2016 Apr; 69(4):624-633. PubMed ID: 26497923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
    Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
    Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
    Lin Z; Fu S; Zhou Y; Zhang X; Chen C; He LN; Li H; Wang Y; Chen T; Zhang L; Hong S
    Lung Cancer; 2019 Nov; 137():100-107. PubMed ID: 31568886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
    Mellema WW; Masen-Poos L; Smit EF; Hendriks LE; Aerts JG; Termeer A; Goosens MJ; Smit HJ; van den Heuvel MM; van der Wekken AJ; Herder GJ; Krouwels FH; Stigt JA; van den Borne BE; Haitjema TJ; Staal-Van den Brekel AJ; van Heemst RC; Pouw E; Dingemans AM
    Lung Cancer; 2015 Nov; 90(2):249-54. PubMed ID: 26415993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
    Xu H; Xu F; Zhu W; Ying J; Wang Y
    Thorac Cancer; 2018 Aug; 9(8):1005-1011. PubMed ID: 29917332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer.
    Manegold C; Koschel G; Hruska D; Scott-von-Römer K; Mezger J; Pilz LR
    Clin Lung Cancer; 2007 Jan; 8(4):245-51. PubMed ID: 17311688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
    Zhai X; Zheng Q; Yang L; Zhu Y; Li J; Liu Y; Wang Z
    Sci Rep; 2017 May; 7(1):1453. PubMed ID: 28469143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
    Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
    Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
    Kalmadi S; McNeill G; Davis M; Peereboom D; Adelstein D; Mekhail T
    Med Oncol; 2006; 23(4):507-13. PubMed ID: 17303909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative Oncology Group.
    Pectasides D; Kalofonos HP; Samantas E; Nicolaides C; Papacostas P; Onyenadum A; Visvikis A; Skarlos D; Fountzilas G
    Anticancer Res; 2001; 21(4B):3005-10. PubMed ID: 11712802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
    Novello S; Falcone A; Crinò L; Rinaldi M; Nardi M; De Marinis F; Tonato M; Tibaldi C; Tinazzi A; Russo F; Grassivaro N; Scagliotti GV
    Lung Cancer; 2009 Dec; 66(3):327-32. PubMed ID: 19329221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
    Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
    Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
    Tada H; Matsui S; Kawahara M; Hosoe S; Hamada C; Fukushima M
    Eur J Cancer Care (Engl); 2008 Mar; 17(2):120-6. PubMed ID: 18302648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
    Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Taipale K; Girvan AC; Visseren-Grul C; Schnabel PA
    Lung Cancer; 2015 May; 88(2):215-22. PubMed ID: 25748103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
    Kotsakis A; Hatzidaki D; Vamvakas L; Vardakis N; Kalykaki A; Bozionelou V; Androulakis N; Kalbakis K; Saridaki Z; Georgoulias V; Agelaki S
    Anticancer Res; 2010 Oct; 30(10):4335-42. PubMed ID: 21036760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.